BRD1

Across TCGA pan-cancer cohorts, BRD1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BRD1 data layer compared with 22 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher BRD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BRD1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LSCC, CCRCC, and HNSC are the cancer types where BRD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.359	0.868	.006	16	view →
CCRCC	OS	Quartile	III,IV	1.000	0.700	.007	13	view →
HNSC	DFS	Tertile	IV	0.546	0.856	.008	8	view →
LUAD	DFS	Quartile	All	0.821	0.995	.006	6	view →
PDAC	DFS	Tertile	III,IV	0.923	0.374	.012	6	view →
GBM	OS	Median	All	0.473	0.313	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BRD1–LSCC (DFS)

Open the LSCC breakdown →